Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US-2017326228-A1 · Nov 16, 2017 · US
US11485759B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11485759-B2 |
| Application number | US-201916427493-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 31, 2019 |
| Priority date | Nov 3, 2014 |
| Publication date | Nov 1, 2022 |
| Grant date | Nov 1, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
Opening claim text (preview).
We claim: 1. A nanostructure, comprising: (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides, wherein the first polypeptides comprise an amino acid sequence that is at least 80% identical to, the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOS:1-34 and identical at least at one half of identified interface positions; Name Amino Acid Sequence I53-34A MEGMDPLAVLAESRLLPLLTVRGGEDLAGLATVLELMGVG SEQ ID ALEITLRTEKGLEALKALRKSGLLLGAGTVRSPKEAEAAE NO: 1 EAGAAFLVSPGLLEEVAALAQARGVPYLPGVLTPTEVERA LALGLSALKFFPAEPFQGVRVLRAYAEVFPEVRFLPTGGI KEEHLPHYAALPNLLAVGGSWLLQGDLAAVMKKVKAAKAL LSPQAPG I53-34B MTKKVGIVDITFARVDMAEAAIRTLKALSPNIKIIRKTVP SEQ ID GIKDLPVACKKLLEEEGCDIVMALGMPGKAEKDKVCAHEA NO: 2 SLGLMLAQLMTNKHIIEVFVHEDEAKDDDELDILALVRAI EHAANVYYLLFKPEYLTRMAGKGLRQGREDAGPARE I53-40A MTKKVGIVDTTFARVDMASAAILTLKMESPNIKIIRKTVP SEQ ID GIKDLPVACKKLLEEEGCDIVMALGMPGKAEKDKVCAHEA NO: 3 SLGLMLAQLMTNKHIIEVFVHEDEAKDDAELKILAARRAI EHALNVYYLLFKPEYLTRMAGKGLRQGFEDAGPARE I53-40B MSTINNQLKALKVIPVIAIDNAEDIIPLGKVLAENGLPAA SEQ ID EITFRSSAAVKAIMLLRSAQPEMUGAGTILNGVQALAAKE NO: 4 AGATFVVSPGFNPNTVRACQIIGIDIVPGVNNPSTVEAAL EMGLTTLKFFPAEASGGISMVKSLVGPYGDIRLMPTGGIT PSNIDNYLAIPQVLACGGTWMVDKKLVTNGEWDEIARLTR EIVEQVNP I53-47A MPIFTLNTNIKATDVPSDFLSLTSRLVGLILSKPGSYVAV SEQ ID HINTDQQLSFGGSTNPAAFGTLMSIGGIEPSKNRDHSAVL NO: 5 FDHENAMEGIPKNRMYIHFVNLNGDDVGWNGTTF I53-47B MNQHSHKDYETVRIAVVRARWHADIVDACVEAFEIAMAAI SEQ ID GGDRFAVDVFDVPGAYEIPLHARTFAETGRYGAVLGTAFV NO: 6 VNGGIYRHEFVASAVIDGMMNVQLSTGVPVLSAVLTPHRY RDSAEHHRFFAAHFAVKGVEAARACIEILAAREKIAA I53-50A MKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIE SEQ ID ITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAV NO: 7 ESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKA MKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVN LDNVCEWFKAGVEAVGVGSALVKGTPDEVREKAKAFVEKI RGCTE I53-50B MNQHSHKDYETVRIAVVRARWHAEIVDACVSAFEAAMADI SEQ ID GGDRFAVDVFDVPGAYEIPLHARTLAETGRYGAVLGTAFV NO: 8 VNGGIYRHEFVASAVIDGMMNVQLSTGVPVLSAVLTPHRY RDSDAHTLLFLALFAVKGMEAARACVEILAAREKIAA I53-51A MFTKSGDDGNTNVINKRVGKDSPLVNFLGDLDELNSFIGF SEQ ID AISKIPWEDMKKDLERVQVELFEIGEDLSTQSSKKKIDES NO: 9 YVLWLLAATAIYRIESGPVKLFVIPGGSEEASVLHVTRSV ARRVERNAVKYTKEEPEINRMIIVYLNRLSSLLFAMALVA NKRRNQSEKIYEIGKSW I53-51B MNQHSHKDYETVRIAVVRARWHADIVDQCVRAFEEAMADA SEQ ID GGDRFAVDVFDVPGAYEIPLHARTLAETGRYGAVLGTAFV NO: 10 VNGGIYRHEFVASAVIDGMMNVQLSTGVPVLSAVLTPHRY RSSREHHEFFREHFMVKGVEAAAACITILAAREKIAA I52-03A MGHTKGPTPQQHDGSALRIGIVHARWNKTIIMPLLIGTIA SEQ ID KLLECGVKASNIVVQSVPGSWELPIAVQRLYSASQLQTPS NO: 11 SGPSLSAGDLLGSSTTDLTALPTTTASSTGPFDALIAIGV EIKGETMFHEYIADSVSHGLMRVQLDTGVPVIFGVLTVLT DDQAKARAGVIEGSHNHGEDWGLAAVEMGVRRRDWAAGKT E I52-03B MYEVDHADVYDLFYLGRGKDYAAEASDIADLVRSRTPEAS SEQ ID SELDVACGTGTHLEMFTKEFGDTAGLELSEDMLTHARKRL NO: 12 PDATLHQGDMRDFQLGRKFSAVVSMFSSVGYEKTVAELGA AVASFAEHLEPGGVVVVEPWWFPETFADGWVSADVVRRDG RTVARVSHSVREGNATRMEVHFTVADPGKGVRHFSDVHLI TLFHQREYEAAFMAAGLRVEYLEGGPSGRGLFVGVPA I52-32A MGMKEKFVLIITHGDFGKGLLSGAEVIIGKQENVHTVGLN SEQ ID LGDNIEKVAKEVMRIIIAKLAEDKEIIIVVDLFGGSPFNI NO: 13 ALEMMKTFDVKVITGINMPMLVELLTSINVYDTTELLENI SKIGKDGIKVIEKSSLKM I52-32B MKYDGSKLRIGILHARWNLEIIAALVAGAIKRLQEFGVKA SEQ ID ENIIIETVPGSFELPYGSKLFVEKQKRLGKPLDAIIPIGV NO: 14 LIKGSTMHFEYICDSTTHQLMKLNFELGIPVIFGVLTCLT DEQAEARAGLIEGKMHNHGEDWGAAAVEMATKFN I52-33A MAVKGLGEVDQKYDGSKLRIGILHARWNRKIILALVAGAV
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.